<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062951" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of pancreatic cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq">Pancreatic Cancer (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000041487">pancreatic cancer</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Pancreatic Cancer Treatment  (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Pancreatic Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000041487">pancreatic cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Pancreatic Cancer</Title><Para id="_9">This summary provides information about the treatment of exocrine pancreatic cancer. Other PDQ summaries containing information related to cancer in the pancreas include the following:</Para><ItemizedList id="_1900" Style="bullet"><ListItem><SummaryRef href="CDR0000062794" url="/types/pancreatic/hp/pnet-treatment-pdq">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062872" url="/types/childhood-cancers/hp/unusual-cancers-childhood-pdq">Unusual Cancers of Childhood Treatment</SummaryRef> (pancreatic cancer during childhood).</ListItem></ItemizedList><SummarySection id="_7"><Title>Incidence and Mortality</Title><Para id="_16">Estimated new cases and deaths from pancreatic cancer in the United States in 2015:<Reference refidx="1"/></Para><ItemizedList id="_17" Style="bullet"><ListItem>New cases: 48,960.</ListItem><ListItem>Deaths: 40,560.</ListItem></ItemizedList><Para id="_18">The incidence of carcinoma of the pancreas has markedly increased over the past several decades and ranks as the fourth leading cause of cancer death in the United States. Despite the high mortality rate associated with pancreatic
cancer, its etiology is poorly understood.<Reference refidx="2"/> </Para></SummarySection><SummarySection id="_1957"><Title>Risk Factors</Title><Para id="_1958">Risk factors for development of pancreatic cancer include the following:<Reference refidx="3"/><Reference refidx="4"/></Para><ItemizedList id="_1959" Style="bullet"><ListItem>A family history of pancreatic cancer.</ListItem><ListItem>Cigarette smoking.</ListItem><ListItem>Obesity.</ListItem><ListItem>Chronic pancreatitis.</ListItem></ItemizedList></SummarySection><SummarySection id="_22"><Title>Anatomy</Title><Para id="_24"><MediaLink ref="CDR0000636528" type="image/jpeg" alt="Pancreas" language="en" thumb="Yes" id="_181" size="half"><Caption language="en">Anatomy of the pancreas.</Caption></MediaLink></Para><Para id="_1901">Cancers of the pancreas are commonly identified by the site of involvement within the pancreas. Surgical approaches differ for masses in the head, body, tail, or uncinate process of the pancreas.</Para></SummarySection><SummarySection id="_29"><Title>Clinical Features</Title><Para id="_31">Pancreatic cancer symptoms depend on the site of the tumor within the pancreas and the degree of tumor involvement. </Para><Para id="_1884">In the early stages of pancreatic cancer there are not many noticeable symptoms. As the cancer grows, symptoms may include the following:</Para><ItemizedList id="_52" Style="bullet"><ListItem>Jaundice.</ListItem><ListItem>Light-colored stools or dark urine.</ListItem><ListItem>Pain in the upper or middle abdomen and back.</ListItem><ListItem>Weight loss for no known reason.</ListItem><ListItem>Loss of appetite.</ListItem><ListItem>Fatigue.</ListItem></ItemizedList></SummarySection><SummarySection id="_38"><Title>Diagnostic and Staging Evaluation</Title><Para id="_1902">Pancreatic cancer is difficult to detect and diagnose for the following reasons:</Para><ItemizedList id="_1903" Style="bullet"><ListItem>There are no noticeable signs or symptoms in the early stages of pancreatic cancer.</ListItem><ListItem>The signs of pancreatic cancer, when present, are like the signs of many other illnesses, such as pancreatitis or an ulcer.</ListItem><ListItem>The pancreas is obscured by other organs in the abdomen and is difficult to visualize clearly on imaging tests.</ListItem></ItemizedList><Para id="_1904">To appropriately treat pancreatic cancer, it is crucial to evaluate whether the cancer can be resected. </Para><SummarySection id="_43"><Title>Imaging</Title><Para id="_192">The use of imaging technology may aid in the diagnosis of pancreatic cancer and in the identification of patients with
disease that is not amenable to resection. Imaging tests that may be used include the following:<Reference refidx="5"/></Para><ItemizedList id="_59" Style="bullet"><ListItem>Helical computed tomographic scan.</ListItem><ListItem>Magnetic resonance imaging scan.</ListItem><ListItem>Endoscopic ultrasound.</ListItem><ListItem>Minimally invasive techniques, such as laparoscopy and laparoscopic ultrasound may be used to decrease the use of laparotomy.<Reference refidx="6"/><Reference refidx="7"/></ListItem></ItemizedList></SummarySection><SummarySection id="_45"><Title>Peritoneal cytology</Title><Para id="_46">In a case series of 228 patients, positive peritoneal cytology had a positive predictive value of 94%, specificity of 98%, and sensitivity of 25% for determining unresectability.<Reference refidx="8"/></Para></SummarySection><SummarySection id="_47"><Title>Tumor markers</Title><Para id="_48">No tumor-specific markers exist for pancreatic cancer; markers such as serum cancer antigen (CA) 19-9 have low specificity. Most patients with pancreatic cancer will have an elevated CA 19-9 at diagnosis. Following or during definitive therapy, the increase of CA 19-9 levels may identify patients with progressive tumor growth.<Reference refidx="9"/>[<LOERef href="CDR0000335143">Level of evidence: 3iDiii</LOERef>] The presence of a normal CA 19-9, however, does not preclude recurrence.</Para></SummarySection></SummarySection><SummarySection id="_49"><Title>Prognosis and Survival</Title><Para id="_1905">The primary factors that influence prognosis are:</Para><ItemizedList id="_1906" Style="bullet"><ListItem>Whether the tumor is localized and can be completely resected.</ListItem><ListItem>Whether the tumor has spread to lymph nodes or elsewhere.</ListItem></ItemizedList><Para id="_1908">Exocrine pancreatic cancer is rarely curable and has an overall survival  (OS) rate of less than 6%.<Reference refidx="10"/></Para><Para id="_1909"> The highest cure rate occurs if the tumor is truly localized to the pancreas; however, this stage of disease accounts for less than 20% of cases. For patients with localized disease and small cancers (&lt;2 cm) with no lymph node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is associated with an  actuarial 5-year survival rate of 18% to 24%.<Reference refidx="11"/>[<LOERef href="CDR0000335138">Level of evidence: 3iA</LOERef>]</Para><Para id="_1910">Surgical resection is the mainstay of curative treatment and provides a survival benefit in patients with small, localized pancreatic tumors. Patients with unresectable, metastatic, or recurrent disease are unlikely to benefit from surgical resection.</Para><Para id="_1981">Pancreatic tumors are resistant to treatment with chemotherapy and radiation.</Para><Para id="_1911">Patients with any stage of pancreatic cancer can appropriately be considered
candidates for clinical trials because of the poor response to chemotherapy,
radiation therapy, and surgery as conventionally used.</Para></SummarySection><SummarySection id="_70"><Title>Palliative Therapy</Title><Para id="_72">Palliation of symptoms may be achieved with conventional treatment.</Para><Para id="_73">Palliative measures that may improve quality of life while not affecting OS include the following:<Reference refidx="12"/><Reference refidx="13"/></Para><ItemizedList id="_74" Style="bullet"><ListItem>Surgical or radiologic biliary decompression.</ListItem><ListItem>Relief of gastric outlet obstruction.</ListItem><ListItem>Pain control.</ListItem><ListItem>Psychological care to address the potentially disabling psychological events associated with the diagnosis and treatment of pancreatic cancer.<Reference refidx="14"/> </ListItem></ItemizedList><Para id="_218">(Refer to the <SummaryRef href="CDR0000062738#_830" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Palliative Interventions</SummaryRef> section of the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.)</Para></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <ExternalRef xref="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</ExternalRef>. Last accessed April 1, 2015.</Citation><Citation idx="2" PMID="10468306" MedlineID="99396382">Silverman DT, Schiffman M, Everhart J, et al.: Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80 (11): 1830-7, 1999.</Citation><Citation idx="3" PMID="11297271">Tersmette AC, Petersen GM, Offerhaus GJ, et al.: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7 (3): 738-44, 2001.</Citation><Citation idx="4" PMID="16204695">Nöthlings U, Wilkens LR, Murphy SP, et al.: Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 97 (19): 1458-65, 2005.</Citation><Citation idx="5" PMID="9576631" MedlineID="98236168">Riker A, Libutti SK, Bartlett DL: Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 6 (3): 157-69, 1997.</Citation><Citation idx="6" PMID="7857143" MedlineID="95160545">John TG, Greig JD, Carter DC, et al.: Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 221 (2): 156-64, 1995.</Citation><Citation idx="7" PMID="9712562" MedlineID="98376407">Minnard EA, Conlon KC, Hoos A, et al.: Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer. Ann Surg 228 (2): 182-7, 1998.</Citation><Citation idx="8" PMID="10195727" MedlineID="99210102">Merchant NB, Conlon KC, Saigo P, et al.: Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 188 (4): 421-6, 1999.</Citation><Citation idx="9" PMID="8873528" MedlineID="97027389">Willett CG, Daly WJ, Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172 (4): 350-2, 1996.</Citation><Citation idx="10" PMID="23335087">Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63 (1): 11-30, 2013.</Citation><Citation idx="11" PMID="9193189" MedlineID="97336438">Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997.</Citation><Citation idx="12" PMID="10359359" MedlineID="99285892">Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.</Citation><Citation idx="13" PMID="11386268" MedlineID="21253960">Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.</Citation><Citation idx="14" PMID="8681300" MedlineID="96300333">Passik SD, Breitbart WS: Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 78 (3 Suppl): 615-26, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_86"><SectMetaData><SpecificDiagnosis ref="CDR0000041487">pancreatic cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Pancreatic Cancer</Title><Para id="_87">Pancreatic cancer includes the following carcinomas:</Para><ItemizedList id="_88" Style="bullet"><ListTitle>Malignant</ListTitle><ListItem>Duct cell carcinoma (90% of all cases).</ListItem><ListItem>Acinar cell carcinoma.</ListItem><ListItem>Adenosquamous carcinoma.</ListItem><ListItem>Cystadenocarcinoma (serous and mucinous types).</ListItem><ListItem>Giant cell carcinoma.</ListItem><ListItem>Invasive adenocarcinoma associated with cystic mucinous neoplasm or intraductal papillary mucinous neoplasm.</ListItem><ListItem>Mixed type (ductal-endocrine or acinar-endocrine).</ListItem><ListItem>Mucinous carcinoma.</ListItem><ListItem>Pancreatoblastoma. </ListItem><ListItem>Papillary-cystic neoplasm (Frantz tumor). This tumor has lower malignant potential and may be cured with surgery alone.<Reference refidx="1"/><Reference refidx="2"/></ListItem><ListItem>Papillary mucinous carcinoma.</ListItem><ListItem>Signet ring carcinoma.</ListItem><ListItem>Small cell carcinoma.</ListItem><ListItem>Unclassified. </ListItem><ListItem>Undifferentiated carcinoma.</ListItem></ItemizedList><ItemizedList id="_89" Style="bullet"><ListTitle>Borderline Malignancies </ListTitle><ListItem>Intraductal papillary mucinous tumor with dysplasia.<Reference refidx="3"/></ListItem><ListItem>Mucinous cystic tumor with dysplasia.</ListItem><ListItem>Pseudopapillary solid tumor.</ListItem></ItemizedList><ReferenceSection><Citation idx="1" PMID="2241565" MedlineID="91053739">Sanchez JA, Newman KD, Eichelberger MR, et al.: The papillary-cystic neoplasm of the pancreas. An increasingly recognized clinicopathologic entity. Arch Surg 125 (11): 1502-5, 1990.</Citation><Citation idx="2" PMID="2171441" MedlineID="91024336">Warshaw AL, Compton CC, Lewandrowski K, et al.: Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 212 (4): 432-43; discussion 444-5, 1990.</Citation><Citation idx="3" PMID="11524584" MedlineID="21415379">Sohn TA, Yeo CJ, Cameron JL, et al.: Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 234 (3): 313-21; discussion 321-2, 2001.</Citation></ReferenceSection></SummarySection><SummarySection id="_90"><SectMetaData><SpecificDiagnosis ref="CDR0000041487">pancreatic cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Pancreatic Cancer</Title><Para id="_91">The staging system for pancreatic exocrine cancer continues to evolve. The importance of staging beyond establishing whether a tumor is resectable is uncertain since state-of-the-art treatment has demonstrated little impact on survival. However, knowledge of the extent of the disease is necessary to communicate a uniform definition of disease. </Para><SummarySection id="_96"><Title>AJCC Stage Groupings and TNM Definitions</Title><Para id="_97">The American Joint Committee on Cancer (AJCC) has designated staging by TNM classification.<Reference refidx="1"/></Para><Table id="_1965"><Title>Table 1.  Definitions of TNM Stage 0<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="33.33%"/><ColSpec ColName="col2" ColNum="2" ColWidth="33.33%"/><ColSpec ColName="col3" ColNum="3" ColWidth="33.33%"/><THead><Row><entry>Stage</entry><entry>TNM</entry><entry>Description</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.


</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>b</Superscript>This also includes the pancreatic intraepithelial neoplasia (PanIN)-3 classification.</entry></Row></TFoot><TBody><Row><entry MoreRows="2">0</entry><entry MoreRows="2">Tis, N0, M0</entry><entry>Tis = Carcinoma <Emphasis>in situ</Emphasis>.<Superscript>b</Superscript></entry></Row><Row><entry>N0 = No regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row></TBody></TGroup></Table><Table id="_1976"><Title>Table 2.  Definitions of TNM Stages IA and IB<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Stage</entry><entry>TNM</entry><entry>Description </entry><entry>Illustration</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.


</entry></Row></TFoot><TBody><Row><entry MoreRows="2">IA</entry><entry MoreRows="2">T1, N0, M0</entry><entry>T1 = Tumor limited to the pancreas, ≤2 cm in greatest dimension. </entry><entry MoreRows="5"><MediaLink ref="CDR0000687928" type="image/jpeg" alt="Stage I pancreatic cancer; drawing on the left shows that stage IA pancreatic cancer is smaller than 2 centimeters. The drawing on the right shows that stage IB pancreatic cancer is larger than 2 centimeters. An inset shows that a 2 centimeter tumor is about the size of a peanut. The duodenum is also shown." language="en" thumb="Yes" id="_1977" size="full"/></entry></Row><Row><entry>N0 = No regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row><Row><entry MoreRows="2">IB</entry><entry MoreRows="2">T2, N0, M0</entry><entry>T2 = Tumor limited to the pancreas, &gt;2 cm in greatest dimension. </entry></Row><Row><entry>N0 = No regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row></TBody></TGroup></Table><Table id="_1968"><Title>Table 3.  Definitions of TNM Stage IIA<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Stage</entry><entry>TNM</entry><entry>Description</entry><entry>Illustration</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.


</entry></Row></TFoot><TBody><Row><entry MoreRows="2">IIA</entry><entry MoreRows="2">T3, N0, M0</entry><entry>T3 = Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. </entry><entry MoreRows="2"><MediaLink ref="CDR0000687932" type="image/jpeg" alt="Stage IIA pancreatic cancer; drawing shows cancer in the pancreas and duodenum. The bile duct and pancreatic duct are also shown." language="en" thumb="Yes" id="_1969" size="full"/></entry></Row><Row><entry>N0 = No regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row></TBody></TGroup></Table><Table id="_1970"><Title>Table 4.  Definitions of TNM Stage IIB<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Stage</entry><entry>TNM</entry><entry>Description</entry><entry>Illustration</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.


</entry></Row></TFoot><TBody><Row><entry MoreRows="8">IIB</entry><entry MoreRows="2">T1, N1, M0</entry><entry>T1 = Tumor limited to the pancreas, ≤2 cm in greatest dimension. </entry><entry MoreRows="8"><MediaLink ref="CDR0000742418" type="image/jpeg" alt="Stage IIB pancreatic cancer; drawing shows cancer in the pancreas and in nearby lymph nodes. Also shown are the bile duct, pancreatic duct, and duodenum." language="en" thumb="Yes" id="_1971" size="full"/></entry></Row><Row><entry>N1 = Regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row><Row><entry MoreRows="2">T2, N1, M0</entry><entry>T2 = Tumor limited to the pancreas, &gt;2 cm in greatest dimension. </entry></Row><Row><entry>N1 = Regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row><Row><entry MoreRows="2">T3, N1, M0</entry><entry>T3 = Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. </entry></Row><Row><entry>N1 = Regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row></TBody></TGroup></Table><Table id="_1972"><Title>Table 5.  Definitions of TNM Stage III<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Stage</entry><entry>TNM</entry><entry>Description</entry><entry>Illustration</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.


</entry></Row></TFoot><TBody><Row><entry MoreRows="4">III</entry><entry MoreRows="4">T4, Any N, M0</entry><entry>T4 = Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor). </entry><entry MoreRows="4"><MediaLink ref="CDR0000687940" type="image/jpeg" alt="Stage III pancreatic cancer; drawing shows cancer in the pancreas, common hepatic artery, and portal vein. Also shown are the celiac axis (trunk), bile duct, pancreatic duct, duodenum, and superior mesenteric artery." language="en" thumb="Yes" id="_1973" size="full"/></entry></Row><Row><entry>NX = Regional lymph nodes cannot be assessed. </entry></Row><Row><entry>N0 = No regional lymph node metastasis. </entry></Row><Row><entry>N1 = Regional lymph node metastasis. </entry></Row><Row><entry>M0 = No distant metastasis. </entry></Row></TBody></TGroup></Table><Table id="_1974"><Title>Table 6. Definitions of TNM Stage IV<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry>Stage</entry><entry>TNM</entry><entry>Description</entry><entry>Illustration</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.


</entry></Row><Row><entry NameEnd="col4" NameSt="col1"><Superscript>b</Superscript>This also includes the pancreatic intraepithelial neoplasia (PanIN)-3 classification.</entry></Row></TFoot><TBody><Row><entry MoreRows="10">IV</entry><entry MoreRows="10">Any T, Any N, M1</entry><entry>TX = Primary tumor cannot be assessed. </entry><entry MoreRows="10"><MediaLink ref="CDR0000687943" type="image/jpeg" alt="Stage IV pancreatic cancer; drawing shows cancer has spread beyond the pancreas. Inset shows cancer spreading through the blood and lymph nodes to the lung, liver, peritoneal cavity, and other parts of the body." language="en" thumb="Yes" id="_1975" size="full"/></entry></Row><Row><entry>T0 = No evidence of primary tumor. </entry></Row><Row><entry>Tis = Carcinoma<Emphasis> in situ</Emphasis>.<Superscript>b</Superscript> </entry></Row><Row><entry>T1 = Tumor limited to the pancreas, ≤2 cm in greatest dimension. </entry></Row><Row><entry>T2 = Tumor limited to the pancreas, &gt;2 cm in greatest dimension. </entry></Row><Row><entry>T3 = Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. </entry></Row><Row><entry>T4 = Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor). </entry></Row><Row><entry>NX = Regional lymph nodes cannot be assessed. </entry></Row><Row><entry>N0 = No regional lymph node metastasis. </entry></Row><Row><entry>N1 = Regional lymph node metastasis. </entry></Row><Row><entry>M1 = Distant metastasis. </entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1">Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</Citation></ReferenceSection></SummarySection><SummarySection id="_99"><SectMetaData><SpecificDiagnosis ref="CDR0000041487">pancreatic cancer</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview for Pancreatic Cancer</Title><Para id="_107">Surgical resection remains the primary modality when feasible; on occasion, resection can lead to long-term survival and provides effective palliation.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>[<LOERef href="CDR0000335138">Level of evidence: 3iA</LOERef>]</Para><Para id="_109">The role of postoperative therapy (chemotherapy with or without chemoradiation therapy) in the management of pancreatic cancer remains controversial because much of the randomized clinical trial data available are statistically underpowered and provide conflicting results.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_1912">Complications of pancreatic cancer include the following:</Para><ItemizedList id="_1913" Style="bullet" Compact="No"><ListItem>Malabsorption: Frequently, malabsorption caused by exocrine insufficiency contributes to malnutrition. Attention to pancreatic enzyme replacement can help alleviate this problem. (Refer to the PDQ summary on <SummaryRef href="CDR0000276584#_4" url="/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq">Nutrition in Cancer Care</SummaryRef> for more information.) </ListItem><ListItem>Pain: Celiac axis and intrapleural nerve blocks can provide highly effective and long-lasting control of pain for some patients. (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.)
</ListItem></ItemizedList><Para id="_1925">The survival rate of patients with any stage of pancreatic exocrine cancer is poor. Clinical trials are appropriate alternatives for treatment of patients with any stage of disease and should be considered before palliative approaches are selected.  </Para><Para id="_112">Information about ongoing clinical trials for pancreatic cancer is available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para><Table id="_183"><Title>Table 7.  Treatment Options for Pancreatic Cancer </Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry Align="Center"><SummaryRef href="CDR0000062951#_96" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Stage (TNM Staging Criteria)</SummaryRef></entry><entry Align="Center">Treatment Options</entry></Row></THead><TBody><Row><entry MoreRows="2">Stage I and stage II pancreatic cancer </entry><entry><SummaryRef href="CDR0000062951#_126" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Surgery</SummaryRef>

</entry></Row><Row><entry><SummaryRef href="CDR0000062951#_128" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Postoperative chemoradiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062951#_1919" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Postoperative chemotherapy</SummaryRef></entry></Row><Row><entry MoreRows="2">Stage III pancreatic cancer </entry><entry><SummaryRef href="CDR0000062951#_1922" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Palliative surgery</SummaryRef>

</entry></Row><Row><entry><SummaryRef href="CDR0000062951#_1928" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemoradiation therapy</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062951#_1936" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemotherapy</SummaryRef></entry></Row><Row><entry MoreRows="1">Stage IV pancreatic cancer </entry><entry><SummaryRef href="CDR0000062951#_1941" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Palliative therapy</SummaryRef>

</entry></Row><Row><entry><SummaryRef href="CDR0000062951#_1944" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemotherapy</SummaryRef>
</entry></Row><Row><entry MoreRows="1">Recurrent pancreatic cancer </entry><entry><SummaryRef href="CDR0000062951#_1949" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Palliative therapy


</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062951#_1952" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemotherapy</SummaryRef></entry></Row></TBody></TGroup></Table><ReferenceSection><Citation idx="1" PMID="7794076" MedlineID="95314420">Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221 (6): 721-31; discussion 731-3, 1995.</Citation><Citation idx="2" PMID="8604907" MedlineID="96199033">Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223 (3): 273-9, 1996.</Citation><Citation idx="3" PMID="9193189" MedlineID="97336438">Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997.</Citation><Citation idx="4" PMID="3567862" MedlineID="87187047">Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59 (12): 2006-10, 1987.</Citation><Citation idx="5" PMID="4015380" MedlineID="85251043">Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (8): 899-903, 1985.</Citation><Citation idx="6" PMID="10615932" MedlineID="20081678">Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (6): 776-82; discussion 782-4, 1999.</Citation><Citation idx="7" PMID="11716884" MedlineID="21574398">Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358 (9293): 1576-85, 2001.</Citation><Citation idx="8" PMID="15028824">Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (12): 1200-10, 2004.</Citation></ReferenceSection></SummarySection><SummarySection id="_120"><SectMetaData><SpecificDiagnosis ref="CDR0000042468">stage I pancreatic cancer</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000042484">stage II pancreatic cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage I and Stage II Pancreatic Cancer Treatment</Title><SummarySection id="_187"><Title>Treatment Options for Stages I and II Pancreatic Cancer</Title><Para id="_201">Treatment options for <SummaryRef href="CDR0000062951#_1976" url="/types/pancreatic/hp/pancreatic-treatment-pdq">stages I and II pancreatic cancer</SummaryRef> include the following:</Para><OrderedList id="_195" Style="Arabic" Compact="No"><ListItem><SummaryRef href="CDR0000062951#_126" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Surgery</SummaryRef>: radical pancreatic resection including:<ItemizedList id="_196" Style="bullet"><ListItem>Whipple procedure (pancreaticoduodenal resection).</ListItem><ListItem>Total pancreatectomy when necessary for adequate margins.</ListItem><ListItem>Distal pancreatectomy for tumors of the body and tail of the pancreas.<Reference refidx="1"/><Reference refidx="2"/></ListItem></ItemizedList></ListItem><ListItem><SummaryRef href="CDR0000062951#_128" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Postoperative chemoradiation therapy</SummaryRef>: radical pancreatic resection followed by 5-fluorouracil (5-FU) chemotherapy and radiation therapy.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></ListItem><ListItem><SummaryRef href="CDR0000062951#_1919" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Postoperative chemotherapy</SummaryRef>: radical pancreatic resection followed by chemotherapy (gemcitabine or 5-FU/leucovorin).<Reference refidx="8"/></ListItem></OrderedList><SummarySection id="_126"><Title>Surgery
</Title><Para id="_1914"> Complete resection can yield 5-year survival rates of 18% to 24%, but ultimate control remains poor because of the high incidence of both local and distant tumor recurrence.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/>[<LOERef href="CDR0000335138">Level of evidence: 3iA</LOERef>]</Para><Para id="_127">Approximately 20% of patients present with pancreatic cancer amenable to local surgical resection, with operative mortality rates of approximately 1% to 16%.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/> Using information from the Medicare claims database, a national cohort study of more than 7,000 patients undergoing pancreaticoduodenectomy between 1992 and 1995 revealed higher in-hospital mortality rates at low-volume hospitals (&lt;1 pancreaticoduodenectomy per year) versus high-volume hospitals (&gt;5 per year) (16% vs. 4%, respectively; <Emphasis>P</Emphasis> &lt; .01).<Reference refidx="12"/></Para></SummarySection><SummarySection id="_128"><Title>Postoperative chemoradiation therapy
</Title><Para id="_129">The role of postoperative therapy (chemotherapy with or without chemoradiation therapy) in the management of this disease remains controversial because much of the randomized clinical trial data available are statistically underpowered and provide conflicting results.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_130">Evidence (postoperative chemoradiation therapy):</Para><Para id="_1915">Several phase III trials examined the potential overall survival (OS) benefit of postoperative adjuvant 5-FU–based chemoradiation therapy:</Para><OrderedList id="_198" Style="Arabic" Compact="No"><ListItem>	Gastrointestinal Study Group (GITSG):   A small randomized trial conducted by the GITSG in 1985 compared surgery alone with surgery followed by chemoradiation.<Reference refidx="3"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>];<Reference refidx="4"/>[<LOERef href="CDR0000335132">Level of evidence: 2A</LOERef>]<ItemizedList id="_1956" Style="bullet"><ListItem>The investigators reported a significant but modest improvement in median-term and long-term survival over resection alone with postoperative bolus 5-FU and regional split-course radiation given at a dose of 40 Gy.</ListItem></ItemizedList></ListItem><ListItem>	European Organization for the Research and Treatment of Cancer  (EORTC): An attempt by the EORTC to reproduce the results of the GITSG trial failed to confirm a significant benefit for adjuvant chemoradiation therapy over resection alone;<Reference refidx="5"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] however, this trial treated patients with pancreatic and periampullary cancers (with a potentially better prognosis).  <ItemizedList id="_1916" Style="bullet" Compact="No"><ListItem>A subset analysis of the patients with primary pancreatic tumors indicated a trend toward improved median, 2-year, and 5-year OS with adjuvant therapy compared with surgery alone (17.1 months, 37%, and 20%, respectively, vs. 12.6 months, 23%, and 10%, respectively; <Emphasis>P</Emphasis> = .09 for median survival).</ListItem></ItemizedList></ListItem><ListItem>An updated analysis of a subsequent European Study for Pancreatic Cancer (ESPAC 1) trial examined only patients who underwent strict randomization after pancreatic resection. The patients were assigned to one of four groups (observation, bolus 5-FU chemotherapy, bolus 5-FU chemoradiation therapy, or chemoradiation therapy followed by additional chemotherapy).<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="17"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]<ItemizedList id="_1917" Style="bullet" Compact="No"><ListItem>With a 2 × 2 factorial design reported at a median follow-up of 47 months, a median survival benefit was observed for only the patients who received postoperative 5-FU chemotherapy. However, these results were difficult to interpret because of a high rate of protocol nonadherence and the lack of a separate analysis for each of the four groups in the 2 × 2 design.</ListItem></ItemizedList></ListItem><ListItem>U.S. Gastrointestinal Intergroup:  The U.S. Gastrointestinal Intergroup has reported the results of a randomized phase III trial (<ProtocolRef href="CDR0000066076" nct_id="NCT00003216">Radiation Therapy Oncology Group (RTOG)-9704</ProtocolRef>)  that included 451 patients with resected pancreatic cancers who were assigned to receive either postoperative infusional 5-FU plus infusional 5-FU and concurrent radiation or adjuvant gemcitabine plus infusional 5-FU and concurrent radiation.<Reference refidx="18"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] The primary endpoints were OS for all patients and OS for patients with pancreatic head tumors. </ListItem><ListItem>A 5-year update of RTOG-9704 reported that  patients with pancreatic head tumors (n = 388) had a median survival and 5-year OS of 20.5 months and 22% survival rate with gemcitabine, versus 17.1 months and 18% with 5-FU (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.67–1.05; <Emphasis>P</Emphasis> = .12).<Reference refidx="19"/>  <ItemizedList id="_1962" Style="bullet"><ListItem>Univariate analysis showed no difference in OS; however, on multivariate analysis, patients on the gemcitabine arm with pancreatic head tumors experienced a trend toward improved OS (<Emphasis>P</Emphasis> = .08).  Distant relapse remained the predominant site of first failure (78%).   </ListItem></ItemizedList></ListItem><ListItem>A secondary analysis of RTOG-9704 explored the correlation of adherence to protocol-specified radiation with patient outcomes. <ItemizedList id="_1963" Style="bullet" Compact="No"><ListItem>Radiation therapy adherence was scored as per protocol (n = 216) and less than per protocol (n = 200).  The major deviation seen was deviation in field size and field placement.  </ListItem><ListItem>For all pancreatic sites, median survival for patients per protocol was significantly longer than patients treated less than per protocol (1.74 years vs. 1.46 years; <Emphasis>P</Emphasis> = .008). </ListItem><ListItem>On multivariate analysis, treatment per protocol correlated more strongly with median survival than assigned treatment arm (<Emphasis>P</Emphasis> = .014).  However, this is an exploratory analysis that cannot control for potential unknown confounders.</ListItem></ItemizedList>  </ListItem></OrderedList><Para id="_1964">The EORTC/U.S. Gastrointestinal Intergroup <ProtocolRef href="CDR0000659092" nct_id="NCT01013649">RTOG-0848</ProtocolRef> phase III adjuvant trial evaluating the impact of chemoradiation after completion of a full course of gemcitabine with or without erlotinib is currently enrolling patients.</Para></SummarySection><SummarySection id="_1919"><Title>Postoperative chemotherapy</Title><Para id="_1882">Evidence (postoperative chemotherapy):</Para><OrderedList id="_1888" Style="Arabic" Compact="No"><ListItem>	Charité Onkologie (CONKO)-001: Results have also been reported from CONKO-001, a multicenter phase III trial of 368 patients with resected pancreatic cancer who were randomly assigned to receive six cycles of adjuvant gemcitabine versus observation.<Reference refidx="20"/>[<LOERef href="CDR0000335129">Level of evidence: 1iiDii</LOERef>] In contrast to the previous trials, the primary endpoint was disease-free survival (DFS). <ItemizedList id="_1920" Style="bullet" Compact="No"><ListItem>Median DFS was 13.4 months in the gemcitabine arm (95% CI, 11.6–15.3) and 6.7 months in the observation arm (95% CI, 6.0–7.5; <Emphasis>P</Emphasis> &lt; .001). In this initial publication of results, there was no significant difference in OS between the gemcitabine arm (median 22.1 months; 95% CI, 18.4–25.8) and the control arm (median 20.2 months; 95% CI, 17–23.4).</ListItem><ListItem>With a median follow-up of 136 months, long-term follow-up of the CONKO-001 study demonstrates a significant improvement in OS that favors gemcitabine (median survival 22.8 months vs. 20.2 months; HR, 0.76; 95% CI, 0.61–0.95, <Emphasis>P</Emphasis> = .01).  Gemcitabine compared with  observation alone yielded improved survival rates at 5 years of 20.7% for the gemcitabine arm versus 10.4% for the observation-alone arm and at 10 years the survival rates  were 12.2% for the  gemcitabine arm versus 7.7% for the observation-alone arm.<Reference refidx="21"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem></ItemizedList></ListItem><ListItem>ESPAC-3: The <ProtocolRef href="CDR0000287023" nct_id="NCT00058201"> ESPAC-3</ProtocolRef> (NCT00058201) trial randomly assigned 1,088 patients who had undergone complete macroscopic resection to either 6 months of 5-FU (425 mg/m<Superscript>2</Superscript>) and leucovorin (20 mg/m<Superscript>2</Superscript>) on days 1 to 5 every 28 days or 6 months of gemcitabine (1,000 mg/m<Superscript>2</Superscript>) on days 1, 8, and 15 every 28 days.<Reference refidx="8"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] <ItemizedList id="_1926" Style="bullet" Compact="No"><ListItem>Median OS was 23.0 months (95% CI,  21.1– 25.0) for patients treated with 5-FU plus leucovorin and 23.6 months (95% CI, 
21.4–26.4) for those treated with gemcitabine (HR = 0.94; 95% CI, 0.81–1.08; <Emphasis>P</Emphasis> = .39).</ListItem></ItemizedList>   </ListItem></OrderedList><Para id="_135">Additional trials are still warranted to determine more effective adjuvant therapy for this disease.</Para></SummarySection></SummarySection><SummarySection id="_188"><Title>Treatment Options Under Clinical Evaluation for Stages I and II Pancreatic Cancer</Title><Para id="_1953">Treatment options under clinical evaluation include the following:</Para><OrderedList id="_197" Style="Arabic" Compact="No">
     <ListItem>Gemcitabine and capecitabine (<ExternalRef xref="http://cancerhelp.cancerresearchuk.org/trials/a-trial-comparing-gemcitabine-alone-with-gemcitabine-and-capecitabine-together-after-surgery-to-remove-cancer-of-the-pancreas?view=PrinterFriendly">ESPAC-4</ExternalRef>).</ListItem><ListItem>Gemcitabine and erlotinib (<ExternalRef xref="http://apps.who.int/trialsearch/trial.aspx?trialid=DRKS00000247">CONKO-005</ExternalRef>).</ListItem><ListItem>Gemcitabine and erlotinib with or without 5-FU/capecitabine-based chemoradiation (<ProtocolRef href="CDR0000659092" nct_id="NCT01013649">RTOG-0848</ProtocolRef>).</ListItem><ListItem>Preoperative chemotherapy and/or radiation therapy.</ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_120_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_120_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=42468&amp;tt=1&amp;format=2&amp;cn=1">stage I pancreatic cancer</ExternalRef> and <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=42484&amp;tt=1&amp;format=2&amp;cn=1">stage II pancreatic cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_120_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1317976" MedlineID="92285828">Dalton RR, Sarr MG, van Heerden JA, et al.: Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 111 (5): 489-94, 1992.</Citation><Citation idx="2" PMID="8651741" MedlineID="96218992">Brennan MF, Moccia RD, Klimstra D: Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 223 (5): 506-11; discussion 511-2, 1996.</Citation><Citation idx="3" PMID="3567862" MedlineID="87187047">Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59 (12): 2006-10, 1987.</Citation><Citation idx="4" PMID="4015380" MedlineID="85251043">Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (8): 899-903, 1985.</Citation><Citation idx="5" PMID="10615932" MedlineID="20081678">Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (6): 776-82; discussion 782-4, 1999.</Citation><Citation idx="6" PMID="11716884" MedlineID="21574398">Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358 (9293): 1576-85, 2001.</Citation><Citation idx="7" PMID="15028824">Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (12): 1200-10, 2004.</Citation><Citation idx="8" PMID="20823433">Neoptolemos JP, Stocken DD, Bassi C, et al.: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304 (10): 1073-81, 2010.</Citation><Citation idx="9" PMID="1987845" MedlineID="91103379">Cameron JL, Crist DW, Sitzmann JV, et al.: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161 (1): 120-4; discussion 124-5, 1991.</Citation><Citation idx="10" PMID="7794076" MedlineID="95314420">Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221 (6): 721-31; discussion 731-3, 1995.</Citation><Citation idx="11" PMID="9193189" MedlineID="97336438">Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997.</Citation><Citation idx="12" PMID="10076608" MedlineID="99175904">Birkmeyer JD, Finlayson SR, Tosteson AN, et al.: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 125 (3): 250-6, 1999.</Citation><Citation idx="13" PMID="8098202" MedlineID="93256635">Cameron JL, Pitt HA, Yeo CJ, et al.: One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217 (5): 430-5; discussion 435-8, 1993.</Citation><Citation idx="14" PMID="11561607" MedlineID="21445510">Spanknebel K, Conlon KC: Advances in the surgical management of pancreatic cancer. Cancer J 7 (4): 312-23, 2001 Jul-Aug.</Citation><Citation idx="15" PMID="11296108" MedlineID="21191693">Balcom JH 4th, Rattner DW, Warshaw AL, et al.: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 136 (4): 391-8, 2001.</Citation><Citation idx="16" PMID="11307091" MedlineID="21203983">Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (6): 567-79, 2000 Nov-Dec.</Citation><Citation idx="17" PMID="15028829">Choti MA: Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med 350 (12): 1249-51, 2004.</Citation><Citation idx="18" PMID="18319412">Regine WF, Winter KA, Abrams RA, et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299 (9): 1019-26, 2008.</Citation><Citation idx="19" PMID="21499862">Regine WF, Winter KA, Abrams R, et al.: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18 (5): 1319-26, 2011.</Citation><Citation idx="20" PMID="17227978">Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (3): 267-77, 2007.</Citation><Citation idx="21" PMID="24104372">Oettle H, Neuhaus P, Hochhaus A, et al.: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310 (14): 1473-81, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_138"><SectMetaData><SpecificDiagnosis ref="CDR0000042505">stage III pancreatic cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage III Pancreatic Cancer Treatment</Title><SummarySection id="_189"><Title>Treatment Options for Stage III Pancreatic Cancer</Title><Para id="_1927">While stage III and stage IV pancreatic cancer are both incurable, the natural history of stage III (locally advanced) disease may be different than it is for stage IV disease.  An autopsy series demonstrated that 30% of patients presenting with stage III disease died without evidence of distant metastases.<Reference refidx="1"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Therefore, investigators have struggled with the question of whether chemoradiation for patients presenting with stage III disease is warranted.</Para><Para id="_1954">Treatment options for <SummaryRef href="CDR0000062951#_1972" url="/types/pancreatic/hp/pancreatic-treatment-pdq">stage III pancreatic cancer</SummaryRef> include the following:</Para><OrderedList id="_208" Style="Arabic" Compact="No"><ListItem><SummaryRef href="CDR0000062951#_1922" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Palliative surgery</SummaryRef>: palliative surgical biliary and/or gastric bypass, percutaneous radiologic biliary stent placement, or endoscopic biliary stent placement.<Reference refidx="2"/><Reference refidx="3"/></ListItem><ListItem><SummaryRef href="CDR0000062951#_1928" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemoradiation therapy</SummaryRef>:<ItemizedList id="_1921" Style="bullet"><ListItem>Chemoradiation followed by chemotherapy. </ListItem><ListItem>Chemotherapy followed by chemoradiation, for patients without metastatic disease.</ListItem></ItemizedList></ListItem><ListItem><SummaryRef href="CDR0000062951#_1936" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemotherapy</SummaryRef>: gemcitabine; gemcitabine and erlotinib; gemcitabine and nab-paclitaxel; or 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).</ListItem></OrderedList><SummarySection id="_1922"><Title>Palliative surgery</Title><Para id="_1924">A significant proportion (approximately one-third) of patients with pancreatic cancer will present with stage III or locally advanced disease.   Patients with stage III pancreatic cancer have tumors that are technically unresectable because of local vessel impingement or invasion by tumor. These patients may benefit from palliation of biliary obstruction by endoscopic, surgical, or radiological means.<Reference refidx="4"/></Para></SummarySection><SummarySection id="_1928"><Title>Chemoradiation therapy</Title><Para id="_1960">The role of chemoradiation in locally advanced pancreatic cancer remains controversial.  Table 8 summarizes phase III randomized studies of chemoradiation for stage III pancreatic cancer.</Para><Table id="_293"><Title>Table 8.  Randomized Studies in Stage III Pancreatic Cancer:  Median Survival</Title><TGroup Cols="6"><ColSpec ColName="col1" ColNum="1" ColWidth="16.66%"/><ColSpec ColName="col2" ColNum="2" ColWidth="16.66%"/><ColSpec ColName="col3" ColNum="3" ColWidth="16.66%"/><ColSpec ColName="col4" ColNum="4" ColWidth="16.66%"/><ColSpec ColName="col5" ColNum="5" ColWidth="16.66%"/><ColSpec ColName="col6" ColNum="6" ColWidth="16.66%"/><THead><Row><entry Align="Center">Trial</entry><entry Align="Center">Regimen</entry><entry Align="Center">Chemoradiation</entry><entry Align="Center">Radiation Alone</entry><entry Align="Center">Chemotherapy Alone</entry><entry Align="Center"><Emphasis>P</Emphasis> Value</entry></Row></THead><TFoot><Row><entry NameEnd="col6" NameSt="col1">5-FU = 5-fluorouracil; ECOG = Eastern Cooperative Oncology Group; FFCD = Fédération Francophone de Cancérologie Digestive; GEM = gemcitabine; GITSG = Gastrointestinal Tumor Study Group; Gy = gray (unit of absorbed radiation of ionizing radiation);  <Emphasis>P</Emphasis> value = probability value; XRT = x-ray or radiation therapy.</entry></Row></TFoot><TBody><Row><entry><Strong>Pre-2000</Strong></entry><entry NameEnd="col6" NameSt="col2"/></Row><Row><entry>GITSG <Reference refidx="5"/></entry><entry>Radiation alone vs. 5-FU/60 Gy XRT</entry><entry>40 weeks</entry><entry>20 weeks</entry><entry/><entry>&lt;.01</entry></Row><Row><entry>ECOG <Reference refidx="6"/></entry><entry>Radiation vs. 5-FU, mitomycin C/59 Gy XRT</entry><entry>8.4 months</entry><entry>7.1 months</entry><entry/><entry> .16</entry></Row><Row><entry><Strong>Post-2000</Strong></entry><entry NameEnd="col6" NameSt="col2"/></Row><Row><entry>FFCD <Reference refidx="7"/> </entry><entry>GEM vs. GEM, cisplatin, 60 Gy XRT</entry><entry>8.6 months</entry><entry/><entry>13 months</entry><entry>.03</entry></Row><Row><entry>ECOG <Reference refidx="8"/></entry><entry>GEM vs. GEM/50.4 Gy XRT</entry><entry>11.1 months</entry><entry/><entry>9.2 months</entry><entry>.017</entry></Row></TBody></TGroup></Table></SummarySection><Para id="_145">Evidence (chemoradiation therapy): </Para><Para id="_1929">Three trials attempted to look at combined modality therapy versus radiation therapy alone.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/> The trials had substantial deficiencies in design or analysis. Initially, the standard of practice was to give chemoradiation therapy based on data from the first two studies; however, with the publication of the third study, standard practice has changed to chemotherapy followed by chemoradiation in the absence of metastases.</Para><OrderedList id="_211" Style="Arabic" Compact="No"><ListItem>Gastrointestinal Tumor Study Group (GITSG)-9273 trial: Prior to 2000, several phase III trials evaluated combined modality therapy versus radiation therapy alone.  Before the use of gemcitabine for patients with locally advanced or metastatic pancreatic cancer, investigators from the GITSG randomly assigned 106 patients with locally advanced pancreatic adenocarcinoma to receive external-beam radiation therapy (EBRT) (60 Gy) alone or concurrent EBRT (either 40 Gy or 60 Gy) plus bolus 5-FU.<Reference refidx="5"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  <ItemizedList id="_1930" Style="bullet" Compact="No"><ListItem>The study was stopped early when the chemoradiation therapy arms were found to have better efficacy. The 1-year survival was 11% for patients who received EBRT alone compared with 38% for patients who received chemoradiation therapy with 40 Gy and 36% for patients who received chemoradiation therapy with 60 Gy.</ListItem><ListItem>After an additional 88 patients were enrolled in the combined modality arms, there was a trend toward improved survival with 60 Gy EBRT plus 5-FU, but the difference in time-to-progression and overall survival (OS) was not statistically significant when compared with the 40 Gy arm.<Reference refidx="9"/></ListItem></ItemizedList></ListItem><ListItem>Eastern Cooperative Oncology Group (ECOG) E-8282 trial: Investigators from the ECOG randomly assigned 114 patients to receive radiation therapy (59.4 Gy) alone or with concurrent infusional 5-FU (1,000 mg/m<Superscript>2</Superscript> daily on days 2–5 and 28–31) plus mitomycin (10 mg/m<Superscript>2</Superscript> on day 2). <Reference refidx="6"/> <ItemizedList id="_1931" Style="bullet" Compact="No"><ListItem>The trial reported  no difference in OS between the two groups.</ListItem></ItemizedList></ListItem><ListItem>Fédération Francophone de Cancérologie Digestive-Société Française de Radiothérapie Oncologie (FFCD-SFRO) trial: As it became clear that radiation therapy alone was an inadequate treatment, investigators evaluated combined modality approaches versus chemotherapy alone. Investigators from the FFCD-SFRO randomly assigned 119 patients to induction chemoradiation therapy (60 Gy in 2 Gy fractions with 300 mg/m<Superscript>2</Superscript>/day of continuous-infusion 5-FU on days 1–5 for 6 weeks and 20 mg/m<Superscript>2</Superscript>/day of cisplatin on days 1–5 during weeks 1 and 5) or induction gemcitabine (1,000 mg/m<Superscript>2</Superscript> weekly for 7 weeks). Maintenance gemcitabine was administered to both groups until stopped by disease progression or treatment discontinuation as a result of toxicity.    <Reference refidx="10"/><LOERef href="CDR0000335125">[Level of evidence: 1iiA]</LOERef><ItemizedList id="_1932" Style="bullet" Compact="No"><ListItem>Median survival was superior in the gemcitabine arm (13 vs. 8.6 months; <Emphasis>P</Emphasis> = .03).</ListItem><ListItem>Nonhematological grade 3 to 4 toxicities (primarily gastrointestinal) were significantly more common in the chemoradiation therapy arm (44% vs. 18%; <Emphasis>P</Emphasis> = .004), and fewer patients completed at least 75% of induction therapy (42% vs. 73%).</ListItem><ListItem>Nonetheless, the survival benefit persisted in a per-protocol analysis of patients receiving at least 75% of planned therapy. Notably, the dose intensity of maintenance gemcitabine was significantly less in the chemoradiation therapy arm because of a greater incidence of grades 3 to 4 hematological toxicities (71% vs. 27%; <Emphasis>P</Emphasis> = .0001).</ListItem><ListItem>As a result of this study, induction chemoradiation therapy has fallen out of favor. </ListItem></ItemizedList></ListItem><ListItem>ECOG: The results of the FFCD-SFRO study stand in contrast to the results of a study from ECOG in which investigators randomly assigned 74 patients to either gemcitabine alone or gemcitabine with radiation followed by gemcitabine.<Reference refidx="8"/> Of note, the study was closed early as the result of poor accrual.   <ItemizedList id="_1933" Style="bullet" Compact="No"><ListItem>The primary endpoint was survival, which was 9.2 months (95% confidence interval [CI], 7.9–11.4 months) and 11.1 months (95% CI, 7.6–15.5 months) for chemotherapy and combined modality therapy, respectively (one-sided <Emphasis>P</Emphasis> = .017 by stratiﬁed log-rank test).</ListItem><ListItem>Grades 4 and 5 toxicity were greater in the chemoradiation therapy arm than in the chemotherapy arm (41% vs. 9%). 

</ListItem></ItemizedList></ListItem><ListItem>Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR): Given the increased toxicity of chemoradiation therapy and the early development of metastatic disease in a large percentage of patients with stage III pancreatic cancer, investigators are pursuing a strategy of selecting patients with localized disease for chemoradiation therapy. With this strategy, the selected patients have an absence of progressive disease locally or systemically after several months of chemotherapy.<Reference refidx="11"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]<ItemizedList id="_1934" Style="bullet" Compact="No"><ListItem>A retrospective analysis of 181 patients enrolled in prospective phase II and III GERCOR studies revealed that 29% had metastatic disease after 3 months of gemcitabine-based chemotherapy.  </ListItem><ListItem>For the remaining 71%, median OS was significantly longer among patients treated with chemoradiation therapy than among patients treated with additional chemotherapy (15.0 months vs. 11.7 months; <Emphasis>P</Emphasis> = .0009).</ListItem></ItemizedList></ListItem></OrderedList><Para id="_1935">Taken together, the FFCD and GERCOR studies provide support for gemcitabine-based chemotherapy for at least 3 months, followed by chemoradiation in the absence of metastatic disease. This approach has yet to be validated in a prospective phase III trial.</Para><SummarySection id="_1936"><Title>Chemotherapy</Title><Para id="_1961">Chemotherapy is the primary treatment modality for patients with locally advanced pancreatic cancers.  Although gemcitabine has long been considered the standard regimen, newer chemotherapy regimens have recently emerged.  </Para><Para id="_1898">Evidence: (chemotherapy):</Para><OrderedList id="_1899" Style="Arabic" Compact="No"><ListItem>Gemcitabine versus 5-FU: Gemcitabine has demonstrated activity in patients with pancreatic
cancer and is a useful palliative agent.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/>  A phase III trial of gemcitabine
versus 5-FU as first-line therapy in patients with advanced or metastatic
adenocarcinoma of the pancreas reported a significant improvement in survival
among patients treated with gemcitabine (1-year survival was 18% with
gemcitabine compared with  2% with 5-FU; <Emphasis>P</Emphasis> = .003).<Reference refidx="13"/>[<LOERef href="CDR0000335125">Level of
evidence: 1iiA</LOERef>]</ListItem><ListItem>Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (<ProtocolRef href="CDR0000652013" nct_id="NCT00026338">CAN-NCIC-PA3</ProtocolRef> [NCT00026338]) that compared gemcitabine alone versus the combination of gemcitabine and erlotinib (100 mg/day) in patients with advanced or metastatic pancreatic carcinomas.<Reference refidx="15"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]<ItemizedList id="_1937" Style="bullet" Compact="No"><ListItem>The addition of erlotinib modestly prolonged survival when combined with gemcitabine versus gemcitabine alone (hazard ratio [HR] = 0.81; 95% CI, 0.69 to 0.99;  <Emphasis>P</Emphasis> = .038).  </ListItem><ListItem>The corresponding median and 1-year survival rates for patients who received  erlotinib versus placebo were 6.2 months and 5.9 months, and 23% versus 17%, respectively.</ListItem></ItemizedList></ListItem><ListItem>Platinum analog  or fluoropyrimidine versus single-agent gemcitabine: Many phase III studies have evaluated a combination regimen with either a platinum analog (cisplatin or oxaliplatin) or fluoropyrimidine versus single-agent gemcitabine.<Reference refidx="16"/><Reference refidx="17"/>  <ItemizedList id="_1938" Style="bullet" Compact="No"><ListItem>Not one of these phase III trials has demonstrated a statistically significant advantage favoring the use of combination chemotherapy in the first-line treatment of metastatic pancreatic cancer.</ListItem></ItemizedList></ListItem><ListItem>Gemcitabine and nab-paclitaxel versus gemcitabine:  A multicenter, international phase III trial (<ProtocolRef href="CDR0000636818" nct_id="NCT00844649">NCT00844649</ProtocolRef>) included 861 patients with metastatic pancreatic adenocarcinoma (Karnofsky Performance Status of ≥70) who had not previously received chemotherapy for metastatic disease.<Reference refidx="18"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1000 mg/m<Superscript>2</Superscript>) and nab-paclitaxel (125 mg/m<Superscript>2</Superscript> of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1000 mg/m<Superscript>2</Superscript> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks). <ItemizedList id="_1984" Style="bullet" Compact="No"><ListItem>The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HR<Subscript>death</Subscript>, 0.72; 95% CI, 0.62–0.83; <Emphasis>P</Emphasis> &lt; .001).</ListItem><ListItem>Median progression-free survival was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HR<Subscript>disease progression</Subscript>, 0.69; 95% CI, 0.58–0.82;  <Emphasis>P</Emphasis> &lt; .001).  </ListItem><ListItem>Nab-paclitaxel/gemcitabine was more toxic than gemcitabine.  The most common grade 3 toxicities were neutropenia (38% in the nab-paclitaxel/gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% in the nab-paclitaxel/gemcitabine group  vs. 1% in the gemcitabine group), and neuropathy (17% in the nab-paclitaxel/gemcitabine group vs. 1% in the gemcitabine group).  Febrile neutropenia occurred in 3% of the  nab-paclitaxel/gemcitabine group versus 1% in the gemcitabine group.  In the nab-paclitaxel/gemcitabine group, the median time from grade 3 neuropathy to grade 1 or resolution was 29 days.  Of patients with grade 3 peripheral neuropathy, 44%  were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event.</ListItem><ListItem>On the basis of this trial, nab-paclitaxel plus gemcitabine is a standard treatment option for patients with advanced pancreatic cancer.  </ListItem><ListItem>	Quality of life data have not yet been published regarding this regimen, and this study does not address the efficacy of nab-paclitaxel/gemcitabine versus FOLFIRINOX.    </ListItem></ItemizedList></ListItem><ListItem>FOLFIRINOX  versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an ECOG performance status score of 0 or 1.<Reference refidx="19"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  The patients   were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m<Superscript>2</Superscript>], irinotecan [180 mg/m<Superscript>2</Superscript>], leucovorin [400 mg/m<Superscript>2</Superscript>], and 5-FU  [400 mg/m<Superscript>2</Superscript>] given  as a bolus followed by 2,400 mg/m<Superscript>2</Superscript> given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m<Superscript>2</Superscript> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).   <ItemizedList id="_1939" Style="bullet" Compact="No"><ListItem>The median OS was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (HR<Subscript>death</Subscript> = 0.57; 95% CI, 0.45–0.73; <Emphasis>P</Emphasis> &lt; .001).</ListItem><ListItem>Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HR for disease progression = 0.47; 95% CI, 0.37–0.59; <Emphasis>P</Emphasis> &lt; .001).</ListItem><ListItem>FOLFIRINOX was more toxic than gemcitabine; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of quality of life, versus 66% in the gemcitabine group (HR = 0.47; 95% CI, 0.30–0.70; <Emphasis>P</Emphasis> &lt; .001). </ListItem><ListItem>On the basis of  this trial, FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer. </ListItem></ItemizedList></ListItem><ListItem>5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial.  The CONKO-003 investigators randomly assigned patients in the second line of chemotherapy to either the OFF regimen or BSC.<Reference refidx="20"/>; <Reference refidx="21"/>[<LOERef href="CDR0000335138">Level of evidence: 3iA</LOERef>]  The OFF regimen consisted of leucovorin (200 mg/m<Superscript>2</Superscript>) followed by 5-FU (2,000 mg/m<Superscript>2</Superscript> [24-hour continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m<Superscript>2</Superscript> on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43.  The trial was terminated early because of  poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC. <ItemizedList id="_1940" Style="bullet" Compact="No"><ListItem>Median survival on second-line chemotherapy was 4.82 months (95% CI, 4.29–5.35) with the OFF treatment regimen  and 2.30 months (95% CI, 1.76–2.83) with BSC alone (HR = 0.45; 95% CI, 0.24–0.83).</ListItem><ListItem>Median OS was 9.09 months for the sequence of gemcitabine (GEM)-OFF and 7.90 months for GEM-BSC.  </ListItem><ListItem>The early closure of the study and the very small number of patients made the <Emphasis>P</Emphasis> values misleading.  Therefore, second-line chemotherapy with the OFF regimen may be falsely associated with improved survival.</ListItem></ItemizedList></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_190"><Title>Treatment Options Under Clinical Evaluation for Stage III Pancreatic Cancer</Title><Para id="_1955">Treatment options under clinical evaluation include the following:</Para><OrderedList id="_209" Style="Arabic" Compact="No"><ListItem>For patients with unresectable tumors, clinical trials evaluating novel agents in combination with chemotherapy or chemoradiation therapy (<ProtocolRef href="CDR0000068986" nct_id="NCT00026104">RTOG-PA-0020 </ProtocolRef> is one example).</ListItem><ListItem>Intraoperative radiation therapy and/or implantation of radioactive sources.<Reference refidx="22"/><Reference refidx="23"/></ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_138_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_138_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=42505&amp;tt=1&amp;format=2&amp;cn=1">stage III pancreatic cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_138_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19273710">Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27 (11): 1806-13, 2009.</Citation><Citation idx="2" PMID="7507656" MedlineID="94127883">van den Bosch RP, van der Schelling GP, Klinkenbijl JH, et al.: Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 219 (1): 18-24, 1994.</Citation><Citation idx="3" PMID="11386268" MedlineID="21253960">Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.</Citation><Citation idx="4" PMID="10359359" MedlineID="99285892">Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.</Citation><Citation idx="5" PMID="426553">A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 189 (2): 205-8, 1979.</Citation><Citation idx="6" PMID="16029791">Cohen SJ, Dobelbower R Jr, Lipsitz S, et al.: A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62 (5): 1345-50, 2005.</Citation><Citation idx="7">Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. [Abstract] J Clin Oncol  24 (Suppl 18): A-4008, 180s, 2006.</Citation><Citation idx="8" PMID="21969502">Loehrer PJ Sr, Feng Y, Cardenes H, et al.: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29 (31): 4105-12, 2011.</Citation><Citation idx="9" PMID="7284971" MedlineID="82025294">Moertel CG, Frytak S, Hahn RG, et al.: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (8): 1705-10, 1981.</Citation><Citation idx="10" PMID="18467316">Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (9): 1592-9, 2008.</Citation><Citation idx="11" PMID="17235048">Huguet F, André T, Hammel P, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25 (3): 326-31, 2007.</Citation><Citation idx="12" PMID="8805925" MedlineID="96399432">Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7 (4): 347-53, 1996.</Citation><Citation idx="13" PMID="9196156" MedlineID="97339557">Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6): 2403-13, 1997.</Citation><Citation idx="14" PMID="10189130" MedlineID="99203013">Storniolo AM, Enas NH, Brown CA, et al.: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (6): 1261-8, 1999.</Citation><Citation idx="15" PMID="17452677">Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15): 1960-6, 2007.</Citation><Citation idx="16" PMID="19581537">Poplin E, Feng Y, Berlin J, et al.: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27 (23): 3778-85, 2009.</Citation><Citation idx="17" PMID="20194854">Colucci G, Labianca R, Di Costanzo F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28 (10): 1645-51, 2010.</Citation><Citation idx="18" PMID="24131140">Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18): 1691-703, 2013.</Citation><Citation idx="19" PMID="21561347">Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817-25, 2011.</Citation><Citation idx="20">Pelzer U, Kubica K, Stieler J, et al.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. [Abstract] J Clin Oncol  26  (Suppl 15): A-4508, 2008.</Citation><Citation idx="21" PMID="21565490">Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47 (11): 1676-81, 2011.</Citation><Citation idx="22" PMID="1657839" MedlineID="92041103">Tepper JE, Noyes D, Krall JM, et al.: Intraoperative radiation therapy of pancreatic carcinoma: a report of RTOG-8505. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 21 (5): 1145-9, 1991.</Citation><Citation idx="23" PMID="11395232" MedlineID="21289027">Reni M, Panucci MG, Ferreri AJ, et al.: Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 50 (3): 651-8, 2001.</Citation></ReferenceSection></SummarySection><SummarySection id="_149"><SectMetaData><SpecificDiagnosis ref="CDR0000042547">stage IV pancreatic cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage IV Pancreatic Cancer Treatment</Title><SummarySection id="_191"><Title>Treatment Options for Stage IV Pancreatic Cancer</Title><Para id="_202">Treatment options for <SummaryRef href="CDR0000062951#_1974" url="/types/pancreatic/hp/pancreatic-treatment-pdq">stage IV pancreatic cancer</SummaryRef> include the following:</Para><OrderedList id="_212" Style="Arabic" Compact="No"><ListItem><SummaryRef href="CDR0000062951#_1941" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Palliative therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062951#_1944" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemotherapy</SummaryRef>: gemcitabine; gemcitabine and erlotinib; or oxaliplatin, irinotecan, leucovorin, and fluorouracil (5-FU) (FOLFIRINOX).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/></ListItem></OrderedList><SummarySection id="_1941"><Title>Palliative therapy</Title><Para id="_1942">Palliative therapy for advanced pancreatic cancer includes the following:</Para><OrderedList id="_1943" Style="Arabic" Compact="No"><ListItem>Pain-relieving procedures (e.g., celiac or intrapleural block) and supportive care.<Reference refidx="11"/></ListItem><ListItem>Palliative surgical biliary bypass, percutaneous radiologic biliary stent placement, or endoscopically placed biliary stents.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/></ListItem></OrderedList></SummarySection><SummarySection id="_1944"><Title>Chemotherapy</Title><Para id="_151">The low objective response rate and lack of survival benefit with current chemotherapy indicates that clinical trials are appropriate treatment of all newly diagnosed patients. Occasionally, patients have palliation of symptoms when treated with chemotherapy with well-tested older drugs, such as 5-FU. Gemcitabine has demonstrated activity in patients with pancreatic cancer and is a useful palliative agent.<Reference refidx="1"/><Reference refidx="15"/><Reference refidx="16"/></Para><Para id="_207">Evidence (chemotherapy): </Para><OrderedList id="_220" Style="Arabic" Compact="No"><ListItem>Gemcitabine versus 5-FU: A phase III trial of gemcitabine versus 5-FU as first-line therapy in patients with advanced or metastatic adenocarcinoma of the pancreas reported a significant improvement in survival among patients treated with gemcitabine (1-year survival was 18% with gemcitabine compared with 2% with 5-FU; <Emphasis>P</Emphasis> = .003).<Reference refidx="15"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]</ListItem><ListItem>Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (<ProtocolRef href="CDR0000652013" nct_id="NCT00026338">CAN-NCIC-PA3</ProtocolRef> [NCT00026338]) that compared gemcitabine alone versus the combination of gemcitabine and erlotinib (100 mg/day) in patients with advanced or metastatic pancreatic carcinomas.<Reference refidx="17"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]    <ItemizedList id="_1945" Style="bullet" Compact="No"><ListItem>The addition of erlotinib modestly prolonged survival when combined with gemcitabine alone  (hazard ratio [HR] = 0.81; 95% confidence interval [CI];  <Emphasis>P</Emphasis> = .038).</ListItem><ListItem>The corresponding median survival rate for patients receiving erlotinib was 6.2 months, versus 5.9 months for patients receiving placebo. The 1-year survival rate for patients receiving erlotinib was 23%, versus 17% for patients receiving placebo.</ListItem></ItemizedList></ListItem><ListItem>Platinum analog  or fluoropyrimidine versus single-agent gemcitabine: Many phase III studies have evaluated a combination regimen with either a platinum analog (cisplatin or oxaliplatin) or fluoropyrimidine versus single-agent gemcitabine.<Reference refidx="18"/><Reference refidx="19"/>  <ItemizedList id="_1946" Style="bullet" Compact="No"><ListItem>Not one of these phase III trials has demonstrated a statistically significant advantage favoring the use of combination chemotherapy in the first-line treatment of metastatic pancreatic cancer.</ListItem></ItemizedList></ListItem><ListItem>Gemcitabine and nab-paclitaxel versus gemcitabine:  A multicenter, international phase III trial (<ProtocolRef href="CDR0000636818" nct_id="NCT00844649">NCT00844649</ProtocolRef>) included 861 patients with metastatic pancreatic adenocarcinoma (Karnofsky Performance Status of ≥70) who had not previously received chemotherapy for metastatic disease.<Reference refidx="20"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m<Superscript>2</Superscript>) and nab-paclitaxel (125 mg/m<Superscript>2</Superscript> of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m<Superscript>2</Superscript> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks). <ItemizedList id="_1985" Style="bullet" Compact="No"><ListItem>The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HR<Subscript>death</Subscript>, 0.72; 95% CI, 0.62–0.83; <Emphasis>P </Emphasis>&lt; .001).</ListItem><ListItem>Median progression-free survival was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HR<Subscript>disease progression</Subscript>, 0.69; 95% CI, 0.58–0.82, <Emphasis>P</Emphasis> &lt; .001).  </ListItem><ListItem>Nab-paclitaxel/gemcitabine was more toxic than gemcitabine.  The most common grade 3 toxicities were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% in the nab-paclitaxel/gemcitabine group vs. 1% in the gemcitabine group), and neuropathy (17% in the nab-paclitaxel/gemcitabine group vs. 1% in the gemcitabine group).  Febrile neutropenia occurred in 3% of the nab-paclitaxel group versus 1% in the gemcitabine group.  In the nab-paclitaxel/gemcitabine group, the median time from grade 3 neuropathy to grade 1 or resolution was 29 days.  Of patients with grade 3 peripheral neuropathy, 44% were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event.</ListItem><ListItem>On the basis of  this trial, nab-paclitaxel plus gemcitabine is a standard treatment option for patients with advanced pancreatic cancer.  </ListItem><ListItem>	Quality of life data have not yet been published regarding this regimen, and this study does not address the efficacy of nab-paclitaxel-gemcitabine versus  FOLFIRINOX.    </ListItem></ItemizedList></ListItem><ListItem>FOLFIRINOX  versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group performance status score of 0 or 1.<Reference refidx="21"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  The patients   were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m<Superscript>2</Superscript>], irinotecan [180 mg/m<Superscript>2</Superscript>], leucovorin [400 mg/m<Superscript>2</Superscript>], and 5-FU [400 mg/m<Superscript>2</Superscript>] given  as a bolus followed by 2,400 mg/m<Superscript>2</Superscript> given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m<Superscript>2</Superscript> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks). <ItemizedList id="_1947" Style="bullet" Compact="No"><ListItem>The median overall survival (OS) was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (HR<Subscript>death</Subscript> = 0.57; 95% CI, 0.45–0.73; <Emphasis>P</Emphasis> &lt; .001). </ListItem><ListItem>Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HR for disease progression = 0.47; 95% CI, 0.37–0.59; <Emphasis>P</Emphasis> &lt; .001). </ListItem><ListItem>FOLFIRINOX was more toxic than gemcitabine; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of quality of life, versus 66% in the gemcitabine group (HR = 0.47; 95% CI, 0.30–0.70; <Emphasis>P</Emphasis> &lt; .001).</ListItem><ListItem>On the basis of  this trial, FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer.</ListItem></ItemizedList></ListItem><ListItem> 5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial.  The CONKO-003 investigators randomly assigned patients in the second line of chemotherapy to either an OFF regimen or BSC.<Reference refidx="22"/>; <Reference refidx="23"/>[<LOERef href="CDR0000335138">Level of evidence: 3iA</LOERef>] The OFF regimen consisted of leucovorin (200 mg/m<Superscript>2</Superscript>) followed by 5-FU (2,000 mg/m<Superscript>2</Superscript> [24 hours continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m<Superscript>2</Superscript> on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43.  The trial was terminated early because of  poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC. <ItemizedList id="_1948" Style="bullet" Compact="No"><ListItem>Median survival on second-line chemotherapy was 4.82 months (95% CI, 4.29–5.35) for the OFF-regimen treatment and 2.30 months (95% CI, 1.76–2.83) with BSC alone (HR = 0.45; 95% CI, 0.24–0.83).</ListItem><ListItem>Median OS was 9.09 months for the sequence of gemcitabine (GEM)-OFF and 7.90 months for GEM-BSC.  </ListItem><ListItem>The early closure of the study and the very small number of patients made the <Emphasis>P</Emphasis> values misleading.  Therefore, second-line chemotherapy with the OFF regimen may be erroneously associated with improved survival.</ListItem></ItemizedList></ListItem></OrderedList></SummarySection></SummarySection><SummarySection id="_152"><Title>Treatment Options Under Clinical Evaluation for Stage IV Pancreatic Cancer</Title><Para id="_213">Treatment options under clinical evaluation include the following:</Para><OrderedList id="_214" Style="Arabic"><ListItem>Clinical trials evaluating new anticancer agents alone or in combination with chemotherapy.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="9"/><Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/></ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_149_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_149_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=42547&amp;tt=1&amp;format=2&amp;cn=1">stage IV pancreatic cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_149_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8805925" MedlineID="96399432">Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7 (4): 347-53, 1996.</Citation><Citation idx="2" PMID="196501" MedlineID="77239366">MacDonald JS, Widerlite L, Schein PS: Biology, diagnosis, and chemotherapeutic management of pancreatic malignancy. Adv Pharmacol Chemother 14: 107-42, 1977.</Citation><Citation idx="3" PMID="6225508" MedlineID="84001831">Bukowski RM, Balcerzak SP, O'Bryan RM, et al.: Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study. Cancer 52 (9): 1577-82, 1983.</Citation><Citation idx="4" PMID="1960554" MedlineID="92071747">DeCaprio JA, Mayer RJ, Gonin R, et al.: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 9 (12): 2128-33, 1991.</Citation><Citation idx="5" PMID="1833042" MedlineID="92005226">Kelsen D, Hudis C, Niedzwiecki D, et al.: A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68 (5): 965-9, 1991.</Citation><Citation idx="6" PMID="3894585" MedlineID="85263722">O'Connell MJ: Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3 (7): 1032-9, 1985.</Citation><Citation idx="7" PMID="1875224" MedlineID="91341536">Crown J, Casper ES, Botet J, et al.: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 9 (9): 1682-6, 1991.</Citation><Citation idx="8" PMID="8554969" MedlineID="96146609">Carmichael J, Fink U, Russell RC, et al.: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73 (1): 101-5, 1996.</Citation><Citation idx="9" PMID="12826247">Haller DG: Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 56 (4 Suppl): 16-23, 2003.</Citation><Citation idx="10" PMID="17947726">Kulke MH, Blaszkowsky LS, Ryan DP, et al.: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25 (30): 4787-92, 2007.</Citation><Citation idx="11" PMID="9501815" MedlineID="98162436">Polati E, Finco G, Gottin L, et al.: Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 85 (2): 199-201, 1998.</Citation><Citation idx="12" PMID="7507656" MedlineID="94127883">van den Bosch RP, van der Schelling GP, Klinkenbijl JH, et al.: Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 219 (1): 18-24, 1994.</Citation><Citation idx="13" PMID="10359359" MedlineID="99285892">Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.</Citation><Citation idx="14" PMID="11386268" MedlineID="21253960">Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.</Citation><Citation idx="15" PMID="9196156" MedlineID="97339557">Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6): 2403-13, 1997.</Citation><Citation idx="16" PMID="10189130" MedlineID="99203013">Storniolo AM, Enas NH, Brown CA, et al.: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (6): 1261-8, 1999.</Citation><Citation idx="17" PMID="17452677">Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15): 1960-6, 2007.</Citation><Citation idx="18" PMID="19581537">Poplin E, Feng Y, Berlin J, et al.: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27 (23): 3778-85, 2009.</Citation><Citation idx="19" PMID="20194854">Colucci G, Labianca R, Di Costanzo F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28 (10): 1645-51, 2010.</Citation><Citation idx="20" PMID="24131140">Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18): 1691-703, 2013.</Citation><Citation idx="21" PMID="21561347">Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817-25, 2011.</Citation><Citation idx="22">Pelzer U, Kubica K, Stieler J, et al.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. [Abstract] J Clin Oncol  26  (Suppl 15): A-4508, 2008.</Citation><Citation idx="23" PMID="21565490">Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47 (11): 1676-81, 2011.</Citation><Citation idx="24" PMID="10885606" MedlineID="20340115">Rougier P, Adenis A, Ducreux M, et al.: A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36 (8): 1016-25, 2000.</Citation><Citation idx="25" PMID="11481349" MedlineID="21374150">Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19 (15): 3447-55, 2001.</Citation><Citation idx="26" PMID="11249034" MedlineID="21144112">Stathopoulos GP, Mavroudis D, Tsavaris N, et al.: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 12 (1): 101-3, 2001.</Citation><Citation idx="27" PMID="11042564" MedlineID="20498872">Feliu J, López Alvarez MP, Jaraiz MA, et al.: Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group. Cancer 89 (8): 1706-13, 2000.</Citation><Citation idx="28" PMID="11870159" MedlineID="21859399">Rocha Lima CM, Savarese D, Bruckner H, et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20 (5): 1182-91, 2002.</Citation><Citation idx="29" PMID="12826040">Smith D, Gallagher N: A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer. Eur J Cancer 39 (10): 1377-83, 2003.</Citation></ReferenceSection></SummarySection><SummarySection id="_162"><SectMetaData><SpecificDiagnosis ref="CDR0000042949">recurrent pancreatic cancer</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Recurrent Pancreatic Cancer Treatment
</Title><SummarySection id="_164"><Title>Treatment Options for Recurrent Pancreatic Cancer</Title><Para id="_203">Treatment options for recurrent pancreatic cancer include the following:</Para><OrderedList id="_215" Style="Arabic" Compact="No"><ListItem><SummaryRef href="CDR0000062951#_1949" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Palliative therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062951#_1952" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Chemotherapy</SummaryRef>: fluorouracil <Reference refidx="1"/> or gemcitabine.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/></ListItem></OrderedList><SummarySection id="_1949"><Title>Palliative therapy</Title><Para id="_1950">Palliative therapy for recurrent pancreatic cancer includes the following:</Para><OrderedList id="_1951" Style="Arabic" Compact="No"><ListItem>Palliative surgical bypass procedures such as endoscopic or radiologically placed stents.<Reference refidx="5"/><Reference refidx="6"/></ListItem><ListItem>Palliative radiation procedures.</ListItem><ListItem>Pain relief by celiac axis nerve or intrapleural block (percutaneous).<Reference refidx="7"/></ListItem><ListItem>Other palliative medical care alone.</ListItem></OrderedList></SummarySection><SummarySection id="_1952"><Title>Chemotherapy</Title><Para id="_163">Chemotherapy occasionally produces objective antitumor response, but the low percentage of significant responses and lack of survival advantage warrant use of therapies under evaluation.<Reference refidx="8"/></Para></SummarySection></SummarySection><SummarySection id="_166"><Title>Treatment Options Under Clinical Evaluation for Recurrent Pancreatic Cancer</Title><Para id="_216">Treatment options under clinical evaluation include the following:</Para><OrderedList id="_217" Style="Arabic" Compact="No"><ListItem>Phase I and II clinical trials evaluating pharmacologic modulation of fluorinated pyrimidines, new anticancer agents, or biological agents.</ListItem></OrderedList></SummarySection><SummarySection id="_TrialSearch_162_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_162_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=42949&amp;tt=1&amp;format=2&amp;cn=1">recurrent pancreatic cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_162_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2579257" MedlineID="85135261">Cullinan SA, Moertel CG, Fleming TR, et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253 (14): 2061-7, 1985.</Citation><Citation idx="2" PMID="8805925" MedlineID="96399432">Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7 (4): 347-53, 1996.</Citation><Citation idx="3" PMID="9196156" MedlineID="97339557">Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6): 2403-13, 1997.</Citation><Citation idx="4" PMID="10189130" MedlineID="99203013">Storniolo AM, Enas NH, Brown CA, et al.: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (6): 1261-8, 1999.</Citation><Citation idx="5" PMID="10359359" MedlineID="99285892">Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.</Citation><Citation idx="6" PMID="11386268" MedlineID="21253960">Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.</Citation><Citation idx="7" PMID="9501815" MedlineID="98162436">Polati E, Finco G, Gottin L, et al.: Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 85 (2): 199-201, 1998.</Citation><Citation idx="8">Royal RE, Wolfe RA, Crane CH: Cancer of the pancreas. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 961-89.</Citation></ReferenceSection></SummarySection><SummarySection id="_178"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (02/06/2015)</Title><Para id="_179">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_1987"><Strong><SummaryRef href="CDR0000062951#_1" url="/types/pancreatic/hp/pancreatic-treatment-pdq">General Information About Pancreatic Cancer</SummaryRef></Strong></Para><Para id="_1988">Updated <SummaryRef href="CDR0000062951#_16" url="/types/pancreatic/hp/pancreatic-treatment-pdq">statistics</SummaryRef> with estimated new cases and deaths for 2015 (cited American Cancer Society as reference 1).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062951#_AboutThis_1" url="http://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pancreatic cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Pancreatic Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Jason E. Faris, MD (Massachusetts General Hospital)</ListItem><ListItem>Jennifer Wo, MD (Massachusetts General Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Pancreatic Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq">http://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-02-06</DateLastModified></Summary>
